Date: 2018-04-23
Type of information: Production agreement
Compound: brilacidin
Company: Innovation Pharmaceuticals (USA - MA) Evonik (Germany)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: production
Action mechanism:
- antibiotic. Brilacidin is the first of a new class of antibiotics called defensin-mimetics. Modeled after the body’s innate host-defense response, this small, non-peptidic, synthetic molecule penetrates bacterial cell wall membranes. Brilacidin also functions in an immunomodulatory capacity, lessening inflammation and promoting healing.
Disease:
Details:
- • On April 23, 2018, Innovation Pharmaceuticals announced that the company has signed a drug supply contract with Evonik Corporation, a world leader in specialty chemicals, for the bulk production of commercial-grade brilacidin to prepare for, as well as expedite, its continued clinical development.
Financial terms:
Latest news:
Is general: Yes
